BTMD Earnings

BTMD reported its FY2025Q3 earnings on 2025-11-05, showcasing a revenue of 48.00M against an estimate of 48.00M, resulting in a 0.42% surprise. The EPS was 0.22, surpassing the expected 0.05 by 340% . The stock experienced a -3.07% price change on the earnings day and a -11.09% change over the next five days, reflecting market reactions to the results.

Following BTMD's FY2025Q3 earnings announcement on 2025-11-05, the stock price moved by -3.07% on the day of the release. Over the subsequent five days, it saw a -11.09% change. Historically, BTMD's stock price tends to shift by an average of +4.49% in the 10 days leading up to earnings and -9.62% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate BTMD’s annual revenue to reach 46.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.41% and EPS estimates Revise Downward by -2.18% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between BTMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.41%, while EPS estimates moved Revise Downward by -2.18% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BTMD's stock price typically moves by +4.49% in the 10 days before its earnings and -9.62% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 46.00M.

The earnings call reveals several concerns: declining net income and adjusted EBITDA, high attrition rates, and procedural revenue decline. Although there's positive cash flow and growth in the supplements business, the lack of clear guidance on procedural growth and high attrition are worrying. The Q&A highlighted ongoing challenges with sales turnover and attrition, which could continue to pressure the stock. Overall, despite some positives, the negatives outweigh them, leading to a negative sentiment.